z-logo
open-access-imgOpen Access
ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C
Author(s) -
Kei Morio,
Michio Imamura,
Yoshiiku Kawakami,
Takashi Nakahara,
Yuko Nagaoki,
Tomokazu Kawaoka,
Masataka Tsuge,
Akira Hiramatsu,
Hiroshi Aikata,
C. Nelson Hayes,
Grace Naswa Makokha,
Hidenori Ochi,
Hajime Amano,
Keiko Arataki,
Takashi Moriya,
Hiroyuki Ito,
Keiji Tsuji,
Hiroshi Kohno,
Koji Waki,
Toru Tamura,
Toshio Nakamura,
Kazuaki Chayama
Publication year - 2016
Publication title -
journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.33
H-Index - 114
eISSN - 1435-5922
pISSN - 0944-1174
DOI - 10.1007/s00535-016-1279-9
Subject(s) - itpa , ribavirin , sofosbuvir , medicine , gastroenterology , pegylated interferon , hepatology , hepatitis c virus , genotype , immunology , biology , virus , genetics , gene
Polymorphisms in the inosine triphosphatase (ITPA) gene is associated with anemia induced by peg-interferon (PEG-IFN) plus ribavirin (RBV) treatment for patients with chronic hepatitis C virus (HCV) infection. However, the effect of ITPA polymorphism on sofosbuvir plus RBV treatment is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom